These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

378 related articles for article (PubMed ID: 25881093)

  • 1. Tumor evolution and intratumor heterogeneity of an epithelial ovarian cancer investigated using next-generation sequencing.
    Lee JY; Yoon JK; Kim B; Kim S; Kim MA; Lim H; Bang D; Song YS
    BMC Cancer; 2015 Feb; 15():85. PubMed ID: 25881093
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Targeted deep sequencing of mucinous ovarian tumors reveals multiple overlapping RAS-pathway activating mutations in borderline and cancerous neoplasms.
    Mackenzie R; Kommoss S; Winterhoff BJ; Kipp BR; Garcia JJ; Voss J; Halling K; Karnezis A; Senz J; Yang W; Prigge ES; Reuschenbach M; Doeberitz MV; Gilks BC; Huntsman DG; Bakkum-Gamez J; McAlpine JN; Anglesio MS
    BMC Cancer; 2015 May; 15():415. PubMed ID: 25986173
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Clonality, Heterogeneity, and Evolution of Synchronous Bilateral Ovarian Cancer.
    Yin X; Jing Y; Cai MC; Ma P; Zhang Y; Xu C; Zhang M; Di W; Zhuang G
    Cancer Res; 2017 Dec; 77(23):6551-6561. PubMed ID: 28972072
    [TBL] [Abstract][Full Text] [Related]  

  • 4. TP53 mutations are common in all subtypes of epithelial ovarian cancer and occur concomitantly with KRAS mutations in the mucinous type.
    Rechsteiner M; Zimmermann AK; Wild PJ; Caduff R; von Teichman A; Fink D; Moch H; Noske A
    Exp Mol Pathol; 2013 Oct; 95(2):235-41. PubMed ID: 23965232
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Molecular characterization of serous ovarian carcinoma using a multigene next generation sequencing cancer panel approach.
    Ab Mutalib NS; Syafruddin SE; Md Zain RR; Mohd Dali AZ; Mohd Yunos RI; Saidin S; Jamal R; Mokhtar NM
    BMC Res Notes; 2014 Nov; 7():805. PubMed ID: 25404506
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Extreme Outlier Analysis Identifies Occult Mitogen-Activated Protein Kinase Pathway Mutations in Patients With Low-Grade Serous Ovarian Cancer.
    Grisham RN; Sylvester BE; Won H; McDermott G; DeLair D; Ramirez R; Yao Z; Shen R; Dao F; Bogomolniy F; Makker V; Sala E; Soumerai TE; Hyman DM; Socci ND; Viale A; Gershenson DM; Farley J; Levine DA; Rosen N; Berger MF; Spriggs DR; Aghajanian CA; Solit DB; Iyer G
    J Clin Oncol; 2015 Dec; 33(34):4099-105. PubMed ID: 26324360
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Massively Parallel Sequencing-Based Clonality Analysis of Synchronous Endometrioid Endometrial and Ovarian Carcinomas.
    Schultheis AM; Ng CK; De Filippo MR; Piscuoglio S; Macedo GS; Gatius S; Perez Mies B; Soslow RA; Lim RS; Viale A; Huberman KH; Palacios JC; Reis-Filho JS; Matias-Guiu X; Weigelt B
    J Natl Cancer Inst; 2016 Jun; 108(6):djv427. PubMed ID: 26832770
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Paclitaxel is necessary for improved survival in epithelial ovarian cancers with homologous recombination gene mutations.
    Jean S; Li J; Katsaros D; Wubbenhorst B; Maxwell KN; Fishbein L; McLane MW; Benedetto C; Canuto EM; Mitra N; Zhang L; Nathanson KL; Tanyi JL
    Oncotarget; 2016 Jul; 7(30):48577-48585. PubMed ID: 27191893
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Comprehensive mutation profiling by next-generation sequencing of effusion fluids from patients with high-grade serous ovarian carcinoma.
    Shah RH; Scott SN; Brannon AR; Levine DA; Lin O; Berger MF
    Cancer Cytopathol; 2015 May; 123(5):289-97. PubMed ID: 25655233
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Distinct evolutionary trajectories of primary high-grade serous ovarian cancers revealed through spatial mutational profiling.
    Bashashati A; Ha G; Tone A; Ding J; Prentice LM; Roth A; Rosner J; Shumansky K; Kalloger S; Senz J; Yang W; McConechy M; Melnyk N; Anglesio M; Luk MT; Tse K; Zeng T; Moore R; Zhao Y; Marra MA; Gilks B; Yip S; Huntsman DG; McAlpine JN; Shah SP
    J Pathol; 2013 Sep; 231(1):21-34. PubMed ID: 23780408
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Intraindividual genomic heterogeneity of high-grade serous carcinoma of the ovary and clinical utility of ascitic cancer cells for mutation profiling.
    Choi YJ; Rhee JK; Hur SY; Kim MS; Lee SH; Chung YJ; Kim TM; Lee SH
    J Pathol; 2017 Jan; 241(1):57-66. PubMed ID: 27741368
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Intra-tumor heterogeneity in TP53 null High Grade Serous Ovarian Carcinoma progression.
    Mota A; Triviño JC; Rojo-Sebastian A; Martínez-Ramírez Á; Chiva L; González-Martín A; Garcia JF; Garcia-Sanz P; Moreno-Bueno G
    BMC Cancer; 2015 Nov; 15():940. PubMed ID: 26620706
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Molecular diagnosis in type I epithelial ovarian cancer.
    Sadłecki P; Walentowicz-Sadłecka M; Grabiec M
    Ginekol Pol; 2017; 88(12):692-697. PubMed ID: 29303228
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Elucidating the pathogenesis of synchronous and metachronous tumors in a woman with endometrioid carcinomas using a whole-exome sequencing approach.
    Wu RC; Veras E; Lin J; Gerry E; Bahadirli-Talbott A; Baras A; Ayhan A; Shih IM; Wang TL
    Cold Spring Harb Mol Case Stud; 2017 Nov; 3(6):. PubMed ID: 29162652
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Genetic analysis of a morphologically heterogeneous ovarian endometrioid carcinoma.
    Geyer FC; Pareja F; Burke KA; Schultheis AM; Hussein YR; Ye J; De Filippo MR; Marchio C; Macedo GS; Piscuoglio S; Lim RS; Toy E; Murali R; Jungbluth AA; Reis-Filho JS; Soslow RA; Weigelt B
    Histopathology; 2017 Sep; 71(3):480-487. PubMed ID: 28417598
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Synchronous Endometrial and Ovarian Carcinomas: Evidence of Clonality.
    Anglesio MS; Wang YK; Maassen M; Horlings HM; Bashashati A; Senz J; Mackenzie R; Grewal DS; Li-Chang H; Karnezis AN; Sheffield BS; McConechy MK; Kommoss F; Taran FA; Staebler A; Shah SP; Wallwiener D; Brucker S; Gilks CB; Kommoss S; Huntsman DG
    J Natl Cancer Inst; 2016 Jun; 108(6):djv428. PubMed ID: 26832771
    [TBL] [Abstract][Full Text] [Related]  

  • 17. POSTN/TGFBI-associated stromal signature predicts poor prognosis in serous epithelial ovarian cancer.
    Karlan BY; Dering J; Walsh C; Orsulic S; Lester J; Anderson LA; Ginther CL; Fejzo M; Slamon D
    Gynecol Oncol; 2014 Feb; 132(2):334-42. PubMed ID: 24368280
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Inter- and intra-tumor profiling of multi-regional colon cancer and metastasis.
    Kogita A; Yoshioka Y; Sakai K; Togashi Y; Sogabe S; Nakai T; Okuno K; Nishio K
    Biochem Biophys Res Commun; 2015 Feb; 458(1):52-6. PubMed ID: 25623536
    [TBL] [Abstract][Full Text] [Related]  

  • 19. TP53 mutation-mediated genomic instability induces the evolution of chemoresistance and recurrence in epithelial ovarian cancer.
    Zhang M; Zhuang G; Sun X; Shen Y; Wang W; Li Q; Di W
    Diagn Pathol; 2017 Feb; 12(1):16. PubMed ID: 28148293
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Exome profiling of primary, metastatic and recurrent ovarian carcinomas in a BRCA1-positive patient.
    Zhang J; Shi Y; Lalonde E; Li L; Cavallone L; Ferenczy A; Gotlieb WH; Foulkes WD; Majewski J
    BMC Cancer; 2013 Mar; 13():146. PubMed ID: 23522120
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 19.